SCHEMBL4245256

SCHEMBL4245256

NS(=O)(=O)c1ccc(-n2nc(OCC(F)(F)F)nc2-c2ccc(F)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 10/20 0.60
PTGS1 P23219 8/20 0.60
CA1 P00915 9/20 0.48
CA2 P00918 9/20 0.48
CA4 P22748 8/20 0.48
CA7 P43166 3/20 0.48
KDR P35968 1/20 0.48
CA9 Q16790 6/20 0.47
CHRNA7 P36544 1/20 0.47
PTGES O14684 1/20 0.46
HDAC3 O15379 1/20 0.46
PDPK1 O15530 1/20 0.46
CA12 O43570 1/20 0.46
PDE5A O76074 1/20 0.46
ABCB11 O95342 1/20 0.46
MT-CO2 P00403 1/20 0.46
LMNA P02545 1/20 0.46
CA3 P07451 1/20 0.46
CYP3A4 P08684 1/20 0.46
ALOX5 P09917 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3354633 0.89 PTGS2 (0.80) PTGS2PTGS1CA1CA2CA4
SCHEMBL4248049 0.87 PTGS2 (0.59) PTGS2PTGS1CA1CA2CA4
SCHEMBL4250920 0.85 PTGS2 (0.52) PTGS2PTGS1CA1CA2CA4
SCHEMBL3353886 0.84 PTGS2 (0.51) PTGS2PTGS1CA1CA2CA4
SCHEMBL4247517 0.84 PTGS2 (0.51) PTGS2PTGS1CA1CA2CA4
SCHEMBL3358257 0.84 PTGS2 (0.52) PTGS2PTGS1CA1CA2CA4
SCHEMBL3359120 0.83 PTGS2 (0.58) PTGS2PTGS1CA1CA2CA4
SCHEMBL5235013 0.83 PTGS2 (0.62) PTGS2PTGS1CA1CA2CA4
SCHEMBL4246273 0.80 PTGS2 (0.54) PTGS2PTGS1CA1CA2CA4
SCHEMBL5205568 0.78 PTGS2 (0.62) PTGS2PTGS1CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473700-B2 1,2,4-triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same CJ CORPORATION (KR) 2009-01-06 US claimed
US-20060074118-A1 1, 2, 4 - Triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same CJ CORPORATION (JP) 2006-04-06 US claimed
US-7473700-B2 1,2,4-triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same CJ CORPORATION (KR) 2009-01-06 US disclosed
US-7473700-B2 1,2,4-triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same CJ CORPORATION (KR) 2009-01-06 US disclosed
US-7473700-B2 1,2,4-triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same CJ CORPORATION (KR) 2009-01-06 US disclosed
US-20060074118-A1 1, 2, 4 - Triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same CJ CORPORATION (JP) 2006-04-06 US disclosed
EP-1565447-A4 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME CJ CORP (KR) 2005-11-16 EP disclosed
EP-1565447-A1 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME CJ Corporation (KR) 2005-08-24 EP disclosed
WO-2004048347-A1 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME CJ CORPORATION (KR) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074118-A1 1, 2, 4 - Triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same CYP4B1, CYP3A4, CYP3A5 PTGS2 2356/4885PTGS1 808/4885CA1 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.